Logo
Regenovue Sub Q Plus with Lidocaine (1 x 1.1 ml)

Regenovue Sub Q Plus with Lidocaine (1 x 1.1 ml)

Regenovue

Dermal filler
  • Regenovue HA dermal filler series (including Sub Q Plus with Lidocaine) is CE certified as a medical device in the European market, as stated by multiple distributors and by NeoGenesis Related materials.
  • The series is produced by NeoGenesis Co., Ltd., a South Korean medical device and pharmaceutical manufacturer that supplies CE Approved hyaluronic acid dermal fillers to global markets.
  • Regenovue fillers are characterised by 100% cross Linked monophasic HA structure with low residual BDDE and low endotoxin levels, in accordance with international safety and quality expectations for injectable dermal fillers.
  • Reseller platforms explicitly list Regenovue as CE Marked and suitable only for professional use, aligning with EU/EEA medical device regulations for class III injectable fillers.
  • Clinics are expected to comply with national regulations on the use of CE Marked injectable fillers, practitioner qualifications, patient consent and pharmacovigilance/complication reporting.
Hyaluronic acid dermal filler for deep wrinkles, severe folds and facial volumising

Description

Regenovue Sub-Q Plus with Lidocaine (1 x 1.1 ml) is a CE-marked, high-density hyaluronic acid dermal filler from the South Korean brand Regenovue, manufactured by NeoGenesis Co., Ltd. It is formulated with 100% cross-linked, non-animal origin hyaluronic acid at 24 mg/ml and 0.3% lidocaine, giving a thick, highly viscous monophasic gel. Designed for injection into the lower subcutaneous layer of the dermis, it is indicated for the correction of deep and severe wrinkles, restoration of facial volume, contouring of cheeks, chin and nose bridge, and treatment of acne scars. The product features ultra-low endotoxin levels and very low residual BDDE, providing a high level of purity and a low risk of adverse reactions. Clinical aesthetic effects are typically long-lasting, with most distributors reporting visible results for around 8–12 months and some specifying 12–18 months depending on individual metabolism and treatment parameters.

Bnefits

  • Correction of deep and severe facial wrinkles and folds (e.g. nasolabial folds, marionette lines, chin folds)
  • Powerful volumising effect for cheeks, cheekbones, chin and other facial areas requiring structural support
  • Improvement and contouring of the nasal bridge (non-surgical rhinoplasty indications within the product’s scope)
  • Treatment of selected acne scars with a dense, stable gel placed in the lower subcutaneous layer
  • Long-lasting aesthetic effect typically 8–12 months, with some sources reporting up to 12–18 months
  • 100% cross-linked hyaluronic acid with high viscosity and elasticity for durable volume and shape retention
  • Monophasic, finely dispersed gel structure for smooth, even injections and natural-looking results
  • Lidocaine content for reduced injection pain and improved patient comfort during procedures
  • Non-animal origin HA with very low endotoxin content (<0.0015 IU/mg) for a favourable safety profile
  • Fully biodegradable and resorbable filler that integrates with skin tissues over time

Indications

  • Deep and severe wrinkles and folds, including nasolabial folds and marionette lines
  • Facial volumetry and contouring (cheeks, cheekbones, chin, jawline, temples)
  • Modeling and improvement of the ridge/bridge of the nose (non-surgical rhinoplasty within practitioner competence)
  • Correction of volume loss in the mid and lower face due to ageing or weight changes
  • Lip augmentation in cases where a dense, structural filler is desired (per some distributor protocols)
  • Treatment of selected atrophic acne scars
  • General restoration of facial contours requiring a dense, high-viscosity HA filler injected into the lower subcutaneous layer

Composition

  • Cross-linked hyaluronic acid (non-animal origin) 24 mg/ml
  • Lidocaine 0.3% (0.3% w/v local anaesthetic in the gel)
  • Highly purified HA with low endotoxin content (<0.0015 IU/mg as reported for the Regenovue line)
  • Very low residual BDDE cross-linker (reported as undetectable in finished product for Regenovue fillers)
  • Physiological buffer and excipients (exact excipient list provided in official product leaflet)

Formulation

  • Monophasic, 100% cross-linked hyaluronic acid gel
  • High viscosity, elastic, dense HA gel designed for lower subcutaneous injection
  • Non-animal origin, biofermentation-derived HA with ultra-low endotoxin content
  • Prefilled sterile 1.1 ml syringe containing HA 24 mg/ml with 0.3% lidocaine
  • Supplied with 25G and 27G sterile needles (or 2 x 27G needles, depending on distributor packaging variant)

Packaging

  • 1 prefilled sterile syringe of 1.1 ml Regenovue Sub-Q Plus with Lidocaine per box
  • Typically supplied with 2 injection needles (commonly 27G x 2; some packaging lists 1 x 25G and 1 x 27G needles)
  • Outer carton labelled as Regenovue Sub-Q Plus (with Lidocaine) CE-certified dermal filler
  • Package leaflet / instructions for use included, indicating indications, precautions, and handling
  • Intended exclusively for professional use by trained medical practitioners or qualified aesthetic clinicians

Usage

  • For professional use only; injector must be a suitably qualified and trained medical professional or aesthetic practitioner experienced with dermal fillers.
  • Intended injection depth is the lower subcutaneous layer of the dermis for deep wrinkle correction and volumising.
  • Common treatment areas include deep nasolabial folds, marionette lines, cheeks, cheekbones, chin, jawline, temples and nasal bridge; product selection and placement should follow manufacturer guidance and practitioner judgement.
  • Before injection, evaluate the patient’s medical history, including allergies (especially to hyaluronic acid or lidocaine), autoimmune conditions, pregnancy and breastfeeding status, and any prior filler treatments.
  • Thoroughly disinfect the treatment area and maintain aseptic technique throughout the procedure.
  • Inject slowly using the supplied fine needles (typically 27G, with some kits also including a 25G needle) using appropriate injection techniques for the indication (e.g. linear threading, fanning, bolus in deep subcutaneous plane).
  • After injection, gently massage the treated area if indicated to ensure even distribution and smooth contours, avoiding excessive pressure.
  • Advise patients on standard post-filler aftercare: avoid makeup on treated areas for several hours, avoid extreme temperatures (sauna, sunbed, ice) for 24–48 hours, and refrain from strong facial massages or strenuous exercise immediately after treatment.
  • Schedule follow-up assessments to evaluate results and determine if touch-up treatment is needed, respecting maximum recommended total volumes per session and area.
  • Always refer to the official instructions for use (IFU) and local clinical guidelines for full, product-specific administration and safety instructions.

Contraindications

  • Women who are pregnant or breastfeeding (as explicitly listed in Regenovue dermal filler contraindication sections)
  • Patients under 18 years of age
  • Known hypersensitivity or allergy to hyaluronic acid
  • Known hypersensitivity or allergy to lidocaine or other amide-type local anaesthetics
  • Patients with a tendency to develop hypertrophic scarring or keloids
  • Injection into or near areas with active skin disease, inflammation or infection (e.g. acne, herpes, dermatitis) at or near the treatment site
  • Use immediately before or after aggressive skin procedures such as laser therapy, chemical peels or dermabrasion on the same area
  • Patients with known severe allergies or anaphylactic history should be assessed with particular caution and may be unsuitable for treatment
  • Any contraindications or warnings listed in the official NeoGenesis/Reginovue instructions for use and in local clinical guidelines must be followed

Adverse Effects

  • Common, usually transient injection-site reactions such as redness, swelling, tenderness, itching, or pain at the treatment area
  • Local bruising or haematoma at injection sites
  • Temporary lumps or irregularities that usually resolve as the product settles or with gentle massage and time
  • Less commonly, delayed swelling or inflammatory reactions; patients should be advised to seek medical attention if symptoms persist or worsen
  • As with all dermal fillers, rare but serious complications such as vascular occlusion, tissue necrosis, or visual disturbance may occur if injected intravascularly; correct injection technique, anatomical knowledge, aspiration and immediate management protocols are essential
  • Hypersensitivity or allergic reactions to HA or lidocaine are possible but uncommon; any signs of systemic reaction require prompt medical management
  • Most distributors emphasise that side effects are generally mild and self-limiting when the product is used by trained professionals and that Regenovue fillers have very low endotoxin and residual BDDE levels to minimise adverse responses

Storage Conditions

  • Store at 2–25°C (36–77°F), as specified in Regenovue product specifications and distributor documentation for Sub-Q Plus and sister products.
  • Keep in the original packaging to protect from light and contamination until use.
  • Do not freeze; freezing may damage the gel structure and compromise product performance.
  • Store in a clean, dry environment away from excessive heat or direct sunlight.
  • Observe the expiry date printed on the packaging and do not use the product after it has expired.
  • Ensure appropriate storage controls are in place according to local regulations for medical devices and injectable products.

Duration

Most distributors report that the aesthetic effect of Regenovue Sub-Q Plus lasts approximately 8\u201312 months, depending on patient factors (age, metabolism, lifestyle, treatment area), with some technical specifications and resellers citing a duration of up to 12\u201318 months for maintained volume in optimal conditions.

Onset

Volumising and wrinkle-correction effects are generally immediate upon injection, with final results becoming apparent after initial post-treatment swelling and redness resolve over the next few days.

Browse more Dermal filler

Top Treatments

Top Cities in the UK